Cargando…
Effects of DPP4 Inhibitors on Renal Outcomes in Diabetes Mellitus: A Systematic Review and Meta-Analysis
OBJECTIVES: This meta-analysis of randomized clinical trials (RCT) intends to evaluate the efficacy of DPP4 Inhibitors (DPP4I) compared with placebo, other antidiabetics (or DPP4I) on renal outcomes, adverse events (AEs), and all-cause mortality. METHODS: We searched relevant scientific database for...
Autores principales: | Dalui, Saikat K., Chakraverty, Raja, Yasmin, Nafisha, Pattanaik, Smita, Pandit, Kaushik, Chatterjee, Suparna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793961/ https://www.ncbi.nlm.nih.gov/pubmed/35136733 http://dx.doi.org/10.4103/ijem.ijem_237_21 |
Ejemplares similares
-
Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients
por: Lu, Yang, et al.
Publicado: (2023) -
Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis
por: Zhao, Yiming, et al.
Publicado: (2017) -
Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis
por: Pal, Rimesh, et al.
Publicado: (2021) -
Diabetes mellitus and the risk of cholangiocarcinoma: an updated meta-analysis
por: Li, Junshan, et al.
Publicado: (2015) -
Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Lou, Yake, et al.
Publicado: (2020)